Advokatfirman Lindahl acts as an adviser in Abboxia’s merger with FrostPharma
Advokatfirman Lindahl represented the sellers of Abboxia in the strategic merger with FrostPharma. The two companies are now merging under the name of FrostPharma and will thus become one of the leading specialist pharmaceutical companies with the widest range of hospital drugs in the Nordic Region.
The merger combines FrostPharma’s commercial strength and strategic alliances with Abboxia’s development capacity, thus allowing more extensive supply of hospital medicines to Nordic healthcare providers.
The Lindahl team consisted of Svante Liljedahl, Olivia Sandin and Jannica Stefansson.
About FrostPharma and Abboxia
FrostPharma, which was founded in 2016, focuses on strategic partnerships and commercialisation of specialist pharmaceuticals in the Nordic market. Abboxia, which was founded in 2017, has developed several specialist medicines for the hospital segment in the Nordic Region.
Read more in the FrostPharma press release here.
Do you want to know more? Contact:
Jannica Stefansson
AssociateCarousel items
-
Cases and transactions
5/14/2025
Lindahl advises Heba in connection with buyback program
Lindahl advises Heba Fastighets AB in connection with the company’s repurchase of its own series B shares.
-
Knowledge
4/30/2025
New rules on review and damages for violations of EU law provisions
The government has decided on a bill proposing amendments to the procurement legislation. Among other things, it is proposed that suppliers' rights to legal remedies, in the form of review and damages, be clarified in the procurement laws concerni...
-
News articles
4/11/2025
Lindahl awarded at the Managing IP Awards
Lindahl has been named the winner in the category Sweden Trademark Prosecution (Law Firms) at the Managing IP EMEA Awards 2025.
-
Read more news and insights?